Section

Glenmark Pharmaceuticals outlays Rs 700 crore capex plan for FY25 to boost growth

By Business Today - 6 months ago
Operationally, Glenmark is targeting an EBITDA margin of approximately 19 percent. The company is also eyeing a double-digit profit after tax (PAT) margin while focusing on sustainable financial performance to provide value to stakeholders.

Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.